Substituted imidazoles as cannabinoid receptor modulators

Details Substituted imidazoles as cannabinoid receptor modulators Substituted imidazoles as cannabinoid receptor modulators

2006-06-06

2006-06-06

Desai, Rita (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C548S333500

Reexamination Certificate

active

07057051

ABSTRACT:
The use of compounds of the present invention as antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor particularly in the treatment, prevention and suppression of diseases mediated by the Cannabinoid-1 (CB1) receptor. The invention is concerned with the use of these novel compounds to selectively antagonize the Cannabinoid-1 (CB1) receptor. As such, compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith. Novel compounds of structural formula (I) are also claimed.

REFERENCES:
patent: 4820757 (1989-04-01), Spang et al.
patent: 4973587 (1990-11-01), Ward et al.
patent: 5013837 (1991-05-01), Ward et al.
patent: 5081122 (1992-01-01), Ward
patent: 5112820 (1992-05-01), Ward
patent: 5260322 (1993-11-01), Nakasima et al.
patent: 5292736 (1994-03-01), Kumar et al.
patent: 5462960 (1995-10-01), Barth et al.
patent: 5532237 (1996-07-01), Gallant et al.
patent: 5624941 (1997-04-01), Barth et al.
patent: 5840721 (1998-11-01), Mjalli et al.
patent: 5925768 (1999-07-01), Barth et al.
patent: 6028084 (2000-02-01), Barth et al.
patent: 6344474 (2002-02-01), Maruani et al.
patent: 2005/0026983 (2005-02-01), Carpino
patent: 2005/0065189 (2005-03-01), Lange et al.
patent: 0 353 606 (1990-02-01), None
patent: 0 284 828 (1991-10-01), None
patent: 0 658 546 (1994-12-01), None
patent: 0 701 819 (1996-03-01), None
patent: 0 576 357 (1997-03-01), None
patent: 0 656 354 (1997-06-01), None
patent: 0 876 350 (2001-07-01), None
patent: 63-010767 (1988-01-01), None
patent: 8-41324 (1996-02-01), None
patent: 9-169737 (1997-06-01), None
patent: 63-107963 (1998-05-01), None
patent: WO 92/05148 (1992-04-01), None
patent: WO 93/19045 (1993-09-01), None
patent: WO 97/29079 (1997-08-01), None
patent: WO 98/27108 (1998-06-01), None
patent: WO 98/31227 (1998-07-01), None
patent: WO 98/37061 (1998-08-01), None
patent: WO 98/41519 (1998-09-01), None
patent: WO 98/43635 (1998-10-01), None
patent: WO 98/43636 (1998-10-01), None
patent: WO 99/02499 (1999-01-01), None
patent: WO 00/10967 (2000-03-01), None
patent: WO 00/10968 (2000-03-01), None
patent: WO 00/33836 (2000-06-01), None
patent: WO 01/28329 (2001-04-01), None
patent: WO 01/28497 (2001-04-01), None
patent: WO 01/28498 (2001-04-01), None
patent: WO 01/28557 (2001-04-01), None
patent: WO 01/29007 (2001-04-01), None
patent: WO 01/58869 (2001-08-01), None
patent: WO 01/64632 (2001-09-01), None
patent: WO 01/64633 (2001-09-01), None
patent: WO 01/64634 (2001-09-01), None
patent: WO 02/03070 (2002-01-01), None
patent: WO 02/24630 (2002-03-01), None
patent: WO 03/007887 (2003-01-01), None
patent: WO 03/027076 (2003-04-01), None
patent: WO 03/037332 (2003-05-01), None
patent: WO 03/040107 (2003-05-01), None
patent: WO 03/082191 (2003-10-01), None
patent: WO 2004/012671 (2004-02-01), None
patent: WO 2004/029204 (2004-04-01), None
patent: WO 2004/058744 (2004-07-01), None
patent: WO 2004/060870 (2004-07-01), None
Little et al., J. of Pharmacol. & Exper. Therapeutics, vol. 247 (1988), pp. 1046-1051, “Pharmacology and stereoselectivity of structurally novel cannabinoids in mice”.
Kuster et al., J. of Pharmacol. & Exper. Therapeutics, vol. 264 (1993), pp. 1352-1363, “Aminoalkylindole binding in rat cerebellum: Selective displacement by natural and synthetic cannabinoids”.
Rinaldi-Carmona et al., FEBS Letters, vol. 350 (1994), pp. 240-244, “SR141716A, a potent and selective antagonist of the brain cannabinoid receptor”.
Rinaldi-Carmona et al., Life Sciences, vol. 56 (1995), pp. 1941-1947, “Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist”.
Portier et al., J. of Pharmacol. & Exper. Therapeutics, vol. 288 (1999), pp. 582-589, “SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist”.
Barth, Exp. Opin. Ther. Patents, vol. 8 (1998), pp. 301-313, “Cannabinoid receptor agonists and antagonists”.
Xiang et al., Annual Reports in Medicinal Chemistry, vol. 34 (1999), pp. 199-208, “Chapter 20. Pharmacology of cannabinoid receptor angonists and antagonists”.
Goya et al., Exp. Opin. Ther. Patents, vol. 10 (2000), pp. 1529-1538, “Recent advances in cannabinoid receptor agonists and antagonists”.
Piomelli et al., Trends in Pharma. Sci., vol. 21 (2000), pp. 218-224, “The endocannabinoid system as a target for therapeutic drugs”.
Gompper et al., “Umsetzungen von Imidazolen mit Isocyanaten”, CHBEAM, Chem. Ber., vol. 92, pp. 550-553 (1959).
Singh, “A Convenient and New One-Step Synthesis of 1-Imidazole-2-Carboxamides”, Heterocycles, vol. 34, No. 12, pp. 2373-2378 (1992).
Lange et al., J. Med. Chem. (received Jun. 4, 2004), pp. A thru P, “Bioisosteric replacement of the pyrazole moiety of rimonabant: Synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists”.
DiMarzo et al., Emerging Ther. Targets, vol. 5 (2001), pp. 241-265, “Endocannabinoids Part I: Molecular basis of endocannabinoid formation, action and inactivation and development of selective inhibitors”.
Petitet et al., Emerging Drugs, vol. 3 (1998), pp. 39-53,“The therapeutic applications of cannabinoid agonists and antagonists”.
Goya et al., Exp. Opin. Ther. Patents, vol. 10 (2000), pp. 1529-1538, “Recent advances in cannabinoid receptor agonists and antagonists”.
Adam et al., Expert Opin. Ther. Patents, vol. 12 (2002), pp. 1475-1489, “Recent advances in the cannabinoids”.

Affiliated with

Also associated with

Rating

Substituted imidazoles as cannabinoid receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted imidazoles as cannabinoid receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted imidazoles as cannabinoid receptor modulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3659035